Abstract: A fuel cap barrier kit is basically provided with a movable barrier and an attachment member. The movable barrier is dimensioned and structured to be attached to a vehicle body at a location in which the movable barrier is disposed in front of a fuel cap and is underneath a filler compartment door. The movable barrier is movable between an inlet accessible position in which the movable barrier permits user access to the fuel cap and an inlet blocking position in which the movable barrier is disposed in front of the fuel cap. The attachment member is configured to fixedly attach the movable barrier to the vehicle body.

Abstract: A fuel cap barrier kit is basically provided with a movable barrier and an attachment member. The movable barrier is dimensioned and structured to be attached to a vehicle body at a location in which the movable barrier is disposed in front of a fuel cap and is underneath a filler compartment door. The movable barrier is movable between an inlet accessible position in which the movable barrier permits user access to the fuel cap and an inlet blocking position in which the movable barrier is disposed in front of the fuel cap. The attachment member is configured to fixedly attach the movable barrier to the vehicle body.

Abstract: A system and method for creating an image object or set from a plurality of captured images. The system comprises an interface for receiving the captured images from a client location, a storage device for storing the images and a processor for converting the received images into a format compatible with the image object. The system may include a user interface for accessing the image object and manipulating or otherwise managing the image object (or image set). According to one embodiment, the system comprises a network-based implementation, such as a web-based implementation for the Internet.

Abstract: Compounds of the formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof, wherein, for example, X is O, S or NH; HET is an optionally substituted C-linked 5-membered heteroaryl ring containing 2 to 4 heteroatoms independently selected from N, O and S; Q is selected from, for example, Q1 and Q2: R2 and R3 are independently hydrogen or fluoro; T is selected from a range of groups, for example, an N-linked (fully unsaturated) 5-membered heteroaryl ring system or a group of formula (TC5): wherein Rc is, for example, R13CO—, R13SO2— or R13CS—; wherein R13 is, for example, optionally substituted (1-10C)alkyl or R14C(O)O(1-6C)alkyl wherein R14 is optionally substituted (1-10C)alkyl; are useful as antibacterial agents; and processes for their manufacture and pharmaceutical compositions containing them are described.

Abstract: Compounds of the formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof, wherein, for example, HET is an N-linked 5-membered, fully or partially unsaturated heterocyclic ring, or HET is an N-linked 6-membered di-hydro-heteroaryl ring; Q is, for example, Q1 or Q2: wherein R2 and R3 are independently hydrogen or fluoro; T is selected from a range of groups, for example a group of the formula (TC7) wherein Rc is, for example, hydrogen, R13CO—, R13SO2— or R13CS—; wherein R13 is, for example, optionally substituted (1-10C)alkyl or R14C(O)O(1-6C)alkyl wherein R14 is optionally substituted (1-10C)alkyl; are useful as antibacterial agents; and processes for their manufacture and pharmaceutical compositions containing them are described.

Abstract: The present invention relates to carbapenems and provides a compound of the formula (I): or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof wherein: R1 is 1-hydroxyethyl, 1-fluoroethyl or hydroxymethyl; R2 is hydrogen or C1-4alkyl; R3 is hydrogen or C1-4alkyl; R4 and R5 are the same or different and are selected from hydrogen, halo, cyano, C1-4alkyl, nitro, hydroxy, carboxy, C1-4alkoxy, C1-4alkoxycarbonyl, aminosulphonyl, C1-4alkylaminosulphonyl, di-C1-4-alkylaminosulphonyl, carbamoyl, C1-4alkylcarbamoyl, di-C1-4 alkylcarbamoyl, trifluoromethyl, sulphonic acid, amino, C1-4alkylamino, di-C1-4alkylamino, C1-4alkanoylamino, C1-4alkanoyl(N—C1-4alkyl)amino, C1-4alkanesulphonamido and C1-4alkylS(O)n— wherein n is zero; one or two: with the proviso that there is no hydroxy or carboxy substituent in a position ortho to the link to —NR3—.

Abstract: A steerable soil penetration system having a steerable penetration head, which compacts and does not cut away the surrounding soil and which is connected to an elongate flexible tubing such that the orientation of the penetration head can be varied relative to the tubing. The elongate tubing and/or a downhole hammer or tractor pushes the penetration head through the subsurface formation. Preferably the tubing is surrounded by a narrow annulus so that buckling of the tubing is inhibited and the tubing protects the pierced hole against caving in.

Abstract: Compounds of the formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof, wherein, for example, HET is an N-linked 5-membered, fully or partially unsaturated heterocyclic ring, or HET is an N-linked 6-membered di-hydro-heteroaryl ring; Q is, for example, Q1 or Q2: wherein R2 and R3 are independently hydrogen or fluoro; T is selected from a range of groups, for example a group of the formula (TC7) wherein Rc is, for example, hydrogen, R13CO—, R13SO2— or R13CS—; wherein R13 is, for example, optionally substituted (1-10C)alkyl or R14C(O)O(1-6C)alkyl wherein R14 is optionally substituted (1-10C)alkyl; are useful as antibacterial agents; and processes for their manufacture and pharmaceutical compositions containing them are described.

Abstract: Compounds of the formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof, wherein, for example, HET is an N-linked 5-membered, fully or partially unsaturated heterocyclic ring, or an N-linked 6-membered di-hydro-heteroaryl ring; and Q is, for example, Q1 or Q2: wherein R2 and R3 are independently hydrogen or fluoro; T is selected, for example, from a group of the formula (TA1) or (TA2): wherein, for example, X1m is O? and X2m is R2s—(E)ms—N—; wherein E is an electron withdrawing group, for example, —SO2— or —CO—; and, for example, R2s is hydrogen or (1-6C)alkyl; are useful as pharmaceutical agents; and processes for their manufacture and pharmaceutical compositions containing them are described.

Abstract: A method of document processing which is fully automated and coordinated from a central cite while many of the task are performed at remote locations is presented. The method employs remote job management to perform job manipulation and editing, archival and retrieval, secure printing, use of virtual printers, static forms overlay, imaging engine scanning, and tandem and cluster printing. The method provides for the ability to create and/or recommend applications that can be easily integrated with a provider's engines in creating a complete printing solution. A system and storage medium for implementing the method are also disclosed.